8-K

Harmony Biosciences Holdings, Inc. (HRMY)

8-K 2023-05-26 For: 2023-05-25
View Original
Added on April 04, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Graphic

FORM 8-K

Graphic

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 25, 2023

Graphic

HARMONY BIOSCIENCES HOLDINGS, INC .

(Exact name of registrant as specified in its charter)

Graphic

Delaware 001-39450 82-2279923
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

630 W. Germantown Pike , Suite 215

Plymouth Meeting , PA **** 19462

(Address of principal executive offices) (Zip Code)

( 484 ) 539-9800

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Graphic

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

**** Trading **** Name of each exchange
Title of each class Symbol(s) on which registered
Common Stock, $0.00001 par value per share HRMY The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07.  Submission of Matters to a Vote of Security Holders.

On May 25, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, stockholders voted on the following three proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 14, 2023.

Proposal 1. The election of the three Class II directors listed below to serve until the Company’s 2026 annual meeting of stockholders and until their successors are duly elected and qualified.

​<br><br>​<br><br>​<br><br>​<br><br>​
Votes For Withheld Broker Non-Votes
Antonio Gracias 41,295,494 11,908,393 463,671
Jack Bech Nielsen 38,571,010 14,632,877 463,671
Andreas Wicki, Ph.D 37,229,122 15,974,765 463,671

Based on the votes set forth above, each of the director nominees was duly elected.

Proposal 2. The ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

Votes For Votes Against Abstain
53,633,333 25,629 8,596

Based on the votes set forth above, the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was duly ratified.

Proposal 3. The approval on a non-binding, advisory basis, of the compensation of the Company’s named executive officers as described in our proxy materials.

Votes For Votes Against Abstain Broker Non-Votes
51,543,958 1,252,960 406,969 463,671

Based on the votes set forth above, the compensation of the Company’s named executive officers has been approved.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HARMONY BIOSCIENCES HOLDINGS, INC.
Date: May 26, 2023 By: /s/ Christian Ulrich
Christian Ulrich
SVP & General Counsel